Hotline: +86-18022463983    020-85206863

Global Radiopharmaceutical for Nuclear Medicine Market Research Report 2026

Published Date: 2026-02-12   |   Pages: 101   |   Tables: 108   |  Medical Care

The global Radiopharmaceutical for Nuclear Medicine market was valued at US$ million in 2025 and is anticipated to reach US$ million by 2032, at a CAGR of %from 2026 to 2032.
The North American market for Radiopharmaceutical for Nuclear Medicine is projected to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
The Asia-Pacific market for Radiopharmaceutical for Nuclear Medicine is projected to rise from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
The global market for Radiopharmaceutical for Nuclear Medicine in Nuclear Medicine Diagnosis is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 to 2032.
Major global companies of Radiopharmaceutical for Nuclear Medicine include NRG, NTP Radioisotopes, JSC Isotope, ANSTO, China National Nuclear Corporation (CNNC), IRE ELIT, Nordion, Polatom, etc. In 2025, the world's top three vendors accounted for approximately % of revenue.
This report delivers a comprehensive overview of the global Radiopharmaceutical for Nuclear Medicine market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Radiopharmaceutical for Nuclear Medicine. The Radiopharmaceutical for Nuclear Medicine market size, estimates, and forecasts are provided in terms of revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Radiopharmaceutical for Nuclear Medicine market comprehensively. Regional market sizes by Type, by Application, , and by player are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Radiopharmaceutical for Nuclear Medicine manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation
By Company
NRG
NTP Radioisotopes
JSC Isotope
ANSTO
China National Nuclear Corporation (CNNC)
IRE ELIT
Nordion
Polatom
Segment by Type
Carbon-14
Technetium-99m
Iodine-131
Iodine-125
Others
Segment by Application
Nuclear Medicine Diagnosis
Nuclear Medicine Treatment
Others
By Region
North America
U.S.
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia & New Zealand
Rest of Asia
Europe
Germany
France
U.K.
Italy
Ireland
Russia
Rest of Europe
Latin America
Mexico
Brazil
Argentina
Rest of Latin America
Middle East & Africa
Israel
United Arab Emirates (UAE)
Saudi Arabia
Rest of MEA
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Summarizes global and regional market size and outlines market dynamics and recent developments, including key drivers, restraints, challenges and risks for industry participants, and relevant policy analysis.
Chapter 3: Provides a detailed view of the competitive landscape for Radiopharmaceutical for Nuclear Medicine companies, covering revenue share, development plans, and mergers and acquisitions.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify blue-ocean opportunities.
Chapter 5: Analyzes segments by Application, detailing the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.
Chapter 6–10: Regional deep dives (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) broken down by country. Each chapter quantifies market size and growth potential by region and key countries, and outlines market development, outlook, addressable space, and capacity.
Chapter 11: Profiles key players, presenting essential information on leading companies, including product/ service offerings, revenue, gross margin, product introductions/portfolios, recent developments, etc.
Chapter 12: Key findings and conclusions of the report.

Research Methodology

The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:


Stage 1 SECONDARY RESEARCH

The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.

 

Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES

After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.

 

Stage 3 ANALYSIS OF THE GATHERED DATA

The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.

 

Stage 4 QUANTITATIVE DATA

The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.

 

Stage 5 QUALITY CONTROL

Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.

 

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Radiopharmaceutical for Nuclear Medicine Market Size Growth Rate by Type: 2021 vs 2025 vs 2032
1.2.2 Carbon-14
1.2.3 Technetium-99m
1.2.4 Iodine-131
1.2.5 Iodine-125
1.2.6 Others
1.3 Market by Application
1.3.1 Global Radiopharmaceutical for Nuclear Medicine Market Growth by Application: 2021 vs 2025 vs 2032
1.3.2 Nuclear Medicine Diagnosis
1.3.3 Nuclear Medicine Treatment
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Radiopharmaceutical for Nuclear Medicine Market Perspective (2021–2032)
2.2 Global Radiopharmaceutical for Nuclear Medicine Growth Trends by Region
2.2.1 Global Radiopharmaceutical for Nuclear Medicine Market Size by Region: 2021 vs 2025 vs 2032
2.2.2 Radiopharmaceutical for Nuclear Medicine Historic Market Size by Region (2021–2026)
2.2.3 Radiopharmaceutical for Nuclear Medicine Forecasted Market Size by Region (2027–2032)
2.3 Radiopharmaceutical for Nuclear Medicine Market Dynamics
2.3.1 Radiopharmaceutical for Nuclear Medicine Industry Trends
2.3.2 Radiopharmaceutical for Nuclear Medicine Market Drivers
2.3.3 Radiopharmaceutical for Nuclear Medicine Market Challenges
2.3.4 Radiopharmaceutical for Nuclear Medicine Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Radiopharmaceutical for Nuclear Medicine Players by Revenue
3.1.1 Global Top Radiopharmaceutical for Nuclear Medicine Players by Revenue (2021–2026)
3.1.2 Global Radiopharmaceutical for Nuclear Medicine Revenue Market Share by Players (2021–2026)
3.2 Global Top Radiopharmaceutical for Nuclear Medicine Players Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
3.3 Global Key Players Ranking by Radiopharmaceutical for Nuclear Medicine Revenue
3.4 Global Radiopharmaceutical for Nuclear Medicine Market Concentration Ratio
3.4.1 Global Radiopharmaceutical for Nuclear Medicine Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Radiopharmaceutical for Nuclear Medicine Revenue in 2025
3.5 Global Key Players of Radiopharmaceutical for Nuclear Medicine Head Offices and Areas Served
3.6 Global Key Players of Radiopharmaceutical for Nuclear Medicine, Products and Applications
3.7 Global Key Players of Radiopharmaceutical for Nuclear Medicine, Date of General Availability (GA)
3.8 Mergers and Acquisitions, Expansion Plans
4 Radiopharmaceutical for Nuclear Medicine Breakdown Data by Type
4.1 Global Radiopharmaceutical for Nuclear Medicine Historic Market Size by Type (2021–2026)
4.2 Global Radiopharmaceutical for Nuclear Medicine Forecasted Market Size by Type (2027–2032)
5 Radiopharmaceutical for Nuclear Medicine Breakdown Data by Application
5.1 Global Radiopharmaceutical for Nuclear Medicine Historic Market Size by Application (2021–2026)
5.2 Global Radiopharmaceutical for Nuclear Medicine Forecasted Market Size by Application (2027–2032)
6 North America
6.1 North America Radiopharmaceutical for Nuclear Medicine Market Size (2021–2032)
6.2 North America Radiopharmaceutical for Nuclear Medicine Market Growth Rate by Country: 2021 vs 2025 vs 2032
6.3 North America Radiopharmaceutical for Nuclear Medicine Market Size by Country (2021–2026)
6.4 North America Radiopharmaceutical for Nuclear Medicine Market Size by Country (2027–2032)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Radiopharmaceutical for Nuclear Medicine Market Size (2021–2032)
7.2 Europe Radiopharmaceutical for Nuclear Medicine Market Growth Rate by Country: 2021 vs 2025 vs 2032
7.3 Europe Radiopharmaceutical for Nuclear Medicine Market Size by Country (2021–2026)
7.4 Europe Radiopharmaceutical for Nuclear Medicine Market Size by Country (2027–2032)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Ireland
8 Asia-Pacific
8.1 Asia-Pacific Radiopharmaceutical for Nuclear Medicine Market Size (2021–2032)
8.2 Asia-Pacific Radiopharmaceutical for Nuclear Medicine Market Growth Rate by Region: 2021 vs 2025 vs 2032
8.3 Asia-Pacific Radiopharmaceutical for Nuclear Medicine Market Size by Region (2021–2026)
8.4 Asia-Pacific Radiopharmaceutical for Nuclear Medicine Market Size by Region (2027–2032)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia & New Zealand
9 Latin America
9.1 Latin America Radiopharmaceutical for Nuclear Medicine Market Size (2021–2032)
9.2 Latin America Radiopharmaceutical for Nuclear Medicine Market Growth Rate by Country: 2021 vs 2025 vs 2032
9.3 Latin America Radiopharmaceutical for Nuclear Medicine Market Size by Country (2021–2026)
9.4 Latin America Radiopharmaceutical for Nuclear Medicine Market Size by Country (2027–2032)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Radiopharmaceutical for Nuclear Medicine Market Size (2021–2032)
10.2 Middle East & Africa Radiopharmaceutical for Nuclear Medicine Market Growth Rate by Country: 2021 vs 2025 vs 2032
10.3 Middle East & Africa Radiopharmaceutical for Nuclear Medicine Market Size by Country (2021–2026)
10.4 Middle East & Africa Radiopharmaceutical for Nuclear Medicine Market Size by Country (2027–2032)
10.5 Israel
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 NRG
11.1.1 NRG Company Details
11.1.2 NRG Business Overview
11.1.3 NRG Radiopharmaceutical for Nuclear Medicine Introduction
11.1.4 NRG Revenue in Radiopharmaceutical for Nuclear Medicine Business (2021–2026)
11.1.5 NRG Recent Development
11.2 NTP Radioisotopes
11.2.1 NTP Radioisotopes Company Details
11.2.2 NTP Radioisotopes Business Overview
11.2.3 NTP Radioisotopes Radiopharmaceutical for Nuclear Medicine Introduction
11.2.4 NTP Radioisotopes Revenue in Radiopharmaceutical for Nuclear Medicine Business (2021–2026)
11.2.5 NTP Radioisotopes Recent Development
11.3 JSC Isotope
11.3.1 JSC Isotope Company Details
11.3.2 JSC Isotope Business Overview
11.3.3 JSC Isotope Radiopharmaceutical for Nuclear Medicine Introduction
11.3.4 JSC Isotope Revenue in Radiopharmaceutical for Nuclear Medicine Business (2021–2026)
11.3.5 JSC Isotope Recent Development
11.4 ANSTO
11.4.1 ANSTO Company Details
11.4.2 ANSTO Business Overview
11.4.3 ANSTO Radiopharmaceutical for Nuclear Medicine Introduction
11.4.4 ANSTO Revenue in Radiopharmaceutical for Nuclear Medicine Business (2021–2026)
11.4.5 ANSTO Recent Development
11.5 China National Nuclear Corporation (CNNC)
11.5.1 China National Nuclear Corporation (CNNC) Company Details
11.5.2 China National Nuclear Corporation (CNNC) Business Overview
11.5.3 China National Nuclear Corporation (CNNC) Radiopharmaceutical for Nuclear Medicine Introduction
11.5.4 China National Nuclear Corporation (CNNC) Revenue in Radiopharmaceutical for Nuclear Medicine Business (2021–2026)
11.5.5 China National Nuclear Corporation (CNNC) Recent Development
11.6 IRE ELIT
11.6.1 IRE ELIT Company Details
11.6.2 IRE ELIT Business Overview
11.6.3 IRE ELIT Radiopharmaceutical for Nuclear Medicine Introduction
11.6.4 IRE ELIT Revenue in Radiopharmaceutical for Nuclear Medicine Business (2021–2026)
11.6.5 IRE ELIT Recent Development
11.7 Nordion
11.7.1 Nordion Company Details
11.7.2 Nordion Business Overview
11.7.3 Nordion Radiopharmaceutical for Nuclear Medicine Introduction
11.7.4 Nordion Revenue in Radiopharmaceutical for Nuclear Medicine Business (2021–2026)
11.7.5 Nordion Recent Development
11.8 Polatom
11.8.1 Polatom Company Details
11.8.2 Polatom Business Overview
11.8.3 Polatom Radiopharmaceutical for Nuclear Medicine Introduction
11.8.4 Polatom Revenue in Radiopharmaceutical for Nuclear Medicine Business (2021–2026)
11.8.5 Polatom Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer

List of Tables
Table 1. Global Radiopharmaceutical for Nuclear Medicine Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032
Table 2. Key Players of Carbon-14
Table 3. Key Players of Technetium-99m
Table 4. Key Players of Iodine-131
Table 5. Key Players of Iodine-125
Table 6. Key Players of Others
Table 7. Global Radiopharmaceutical for Nuclear Medicine Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032
Table 8. Global Radiopharmaceutical for Nuclear Medicine Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 9. Global Radiopharmaceutical for Nuclear Medicine Market Size by Region (US$ Million), 2021–2026
Table 10. Global Radiopharmaceutical for Nuclear Medicine Market Share by Region (2021–2026)
Table 11. Global Radiopharmaceutical for Nuclear Medicine Forecasted Market Size by Region (US$ Million), 2027–2032
Table 12. Global Radiopharmaceutical for Nuclear Medicine Market Share by Region (2027–2032)
Table 13. Radiopharmaceutical for Nuclear Medicine Market Trends
Table 14. Radiopharmaceutical for Nuclear Medicine Market Drivers
Table 15. Radiopharmaceutical for Nuclear Medicine Market Challenges
Table 16. Radiopharmaceutical for Nuclear Medicine Market Restraints
Table 17. Global Radiopharmaceutical for Nuclear Medicine Revenue by Players (US$ Million), 2021–2026
Table 18. Global Radiopharmaceutical for Nuclear Medicine Market Share by Players (2021–2026)
Table 19. Global Top Radiopharmaceutical for Nuclear Medicine Players by Tier (Tier 1, Tier 2, and Tier 3), based on Radiopharmaceutical for Nuclear Medicine Revenue, 2025
Table 20. Ranking of Global Top Radiopharmaceutical for Nuclear Medicine Companies by Revenue (US$ Million) in 2025
Table 21. Global 5 Largest Players Market Share by Radiopharmaceutical for Nuclear Medicine Revenue (CR5 and HHI), 2021–2026
Table 22. Global Key Players of Radiopharmaceutical for Nuclear Medicine, Headquarters and Area Served
Table 23. Global Key Players of Radiopharmaceutical for Nuclear Medicine, Products and Applications
Table 24. Global Key Players of Radiopharmaceutical for Nuclear Medicine, Date of General Availability (GA)
Table 25. Mergers and Acquisitions, Expansion Plans
Table 26. Global Radiopharmaceutical for Nuclear Medicine Market Size by Type (US$ Million), 2021–2026
Table 27. Global Radiopharmaceutical for Nuclear Medicine Revenue Market Share by Type (2021–2026)
Table 28. Global Radiopharmaceutical for Nuclear Medicine Forecasted Market Size by Type (US$ Million), 2027–2032
Table 29. Global Radiopharmaceutical for Nuclear Medicine Revenue Market Share by Type (2027–2032)
Table 30. Global Radiopharmaceutical for Nuclear Medicine Market Size by Application (US$ Million), 2021–2026
Table 31. Global Radiopharmaceutical for Nuclear Medicine Revenue Market Share by Application (2021–2026)
Table 32. Global Radiopharmaceutical for Nuclear Medicine Forecasted Market Size by Application (US$ Million), 2027–2032
Table 33. Global Radiopharmaceutical for Nuclear Medicine Revenue Market Share by Application (2027–2032)
Table 34. North America Radiopharmaceutical for Nuclear Medicine Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 35. North America Radiopharmaceutical for Nuclear Medicine Market Size by Country (US$ Million), 2021–2026
Table 36. North America Radiopharmaceutical for Nuclear Medicine Market Size by Country (US$ Million), 2027–2032
Table 37. Europe Radiopharmaceutical for Nuclear Medicine Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 38. Europe Radiopharmaceutical for Nuclear Medicine Market Size by Country (US$ Million), 2021–2026
Table 39. Europe Radiopharmaceutical for Nuclear Medicine Market Size by Country (US$ Million), 2027–2032
Table 40. Asia-Pacific Radiopharmaceutical for Nuclear Medicine Market Size Growth Rate by Region (US$ Million): 2021 vs 2025 vs 2032
Table 41. Asia-Pacific Radiopharmaceutical for Nuclear Medicine Market Size by Region (US$ Million), 2021–2026
Table 42. Asia-Pacific Radiopharmaceutical for Nuclear Medicine Market Size by Region (US$ Million), 2027–2032
Table 43. Latin America Radiopharmaceutical for Nuclear Medicine Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 44. Latin America Radiopharmaceutical for Nuclear Medicine Market Size by Country (US$ Million), 2021–2026
Table 45. Latin America Radiopharmaceutical for Nuclear Medicine Market Size by Country (US$ Million), 2027–2032
Table 46. Middle East & Africa Radiopharmaceutical for Nuclear Medicine Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 47. Middle East & Africa Radiopharmaceutical for Nuclear Medicine Market Size by Country (US$ Million), 2021–2026
Table 48. Middle East & Africa Radiopharmaceutical for Nuclear Medicine Market Size by Country (US$ Million), 2027–2032
Table 49. NRG Company Details
Table 50. NRG Business Overview
Table 51. NRG Radiopharmaceutical for Nuclear Medicine Product
Table 52. NRG Revenue in Radiopharmaceutical for Nuclear Medicine Business (US$ Million), 2021–2026
Table 53. NRG Recent Development
Table 54. NTP Radioisotopes Company Details
Table 55. NTP Radioisotopes Business Overview
Table 56. NTP Radioisotopes Radiopharmaceutical for Nuclear Medicine Product
Table 57. NTP Radioisotopes Revenue in Radiopharmaceutical for Nuclear Medicine Business (US$ Million), 2021–2026
Table 58. NTP Radioisotopes Recent Development
Table 59. JSC Isotope Company Details
Table 60. JSC Isotope Business Overview
Table 61. JSC Isotope Radiopharmaceutical for Nuclear Medicine Product
Table 62. JSC Isotope Revenue in Radiopharmaceutical for Nuclear Medicine Business (US$ Million), 2021–2026
Table 63. JSC Isotope Recent Development
Table 64. ANSTO Company Details
Table 65. ANSTO Business Overview
Table 66. ANSTO Radiopharmaceutical for Nuclear Medicine Product
Table 67. ANSTO Revenue in Radiopharmaceutical for Nuclear Medicine Business (US$ Million), 2021–2026
Table 68. ANSTO Recent Development
Table 69. China National Nuclear Corporation (CNNC) Company Details
Table 70. China National Nuclear Corporation (CNNC) Business Overview
Table 71. China National Nuclear Corporation (CNNC) Radiopharmaceutical for Nuclear Medicine Product
Table 72. China National Nuclear Corporation (CNNC) Revenue in Radiopharmaceutical for Nuclear Medicine Business (US$ Million), 2021–2026
Table 73. China National Nuclear Corporation (CNNC) Recent Development
Table 74. IRE ELIT Company Details
Table 75. IRE ELIT Business Overview
Table 76. IRE ELIT Radiopharmaceutical for Nuclear Medicine Product
Table 77. IRE ELIT Revenue in Radiopharmaceutical for Nuclear Medicine Business (US$ Million), 2021–2026
Table 78. IRE ELIT Recent Development
Table 79. Nordion Company Details
Table 80. Nordion Business Overview
Table 81. Nordion Radiopharmaceutical for Nuclear Medicine Product
Table 82. Nordion Revenue in Radiopharmaceutical for Nuclear Medicine Business (US$ Million), 2021–2026
Table 83. Nordion Recent Development
Table 84. Polatom Company Details
Table 85. Polatom Business Overview
Table 86. Polatom Radiopharmaceutical for Nuclear Medicine Product
Table 87. Polatom Revenue in Radiopharmaceutical for Nuclear Medicine Business (US$ Million), 2021–2026
Table 88. Polatom Recent Development
Table 89. Research Programs/Design for This Report
Table 90. Key Data Information from Secondary Sources
Table 91. Key Data Information from Primary Sources
Table 92. Authors List of This Report


List of Figures
Figure 1. Radiopharmaceutical for Nuclear Medicine Picture
Figure 2. Global Radiopharmaceutical for Nuclear Medicine Market Size Comparison by Type (US$ Million), 2021–2032
Figure 3. Global Radiopharmaceutical for Nuclear Medicine Market Share by Type: 2025 vs 2032
Figure 4. Carbon-14 Features
Figure 5. Technetium-99m Features
Figure 6. Iodine-131 Features
Figure 7. Iodine-125 Features
Figure 8. Others Features
Figure 9. Global Radiopharmaceutical for Nuclear Medicine Market Size by Application (US$ Million), 2021–2032
Figure 10. Global Radiopharmaceutical for Nuclear Medicine Market Share by Application: 2025 vs 2032
Figure 11. Nuclear Medicine Diagnosis Case Studies
Figure 12. Nuclear Medicine Treatment Case Studies
Figure 13. Others Case Studies
Figure 14. Radiopharmaceutical for Nuclear Medicine Report Years Considered
Figure 15. Global Radiopharmaceutical for Nuclear Medicine Market Size (US$ Million), Year-over-Year: 2021–2032
Figure 16. Global Radiopharmaceutical for Nuclear Medicine Market Size, (US$ Million), 2021 vs 2025 vs 2032
Figure 17. Global Radiopharmaceutical for Nuclear Medicine Market Share by Region: 2025 vs 2032
Figure 18. Global Radiopharmaceutical for Nuclear Medicine Market Share by Players in 2025
Figure 19. Global Radiopharmaceutical for Nuclear Medicine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 20. The Top 10 and 5 Players Market Share by Radiopharmaceutical for Nuclear Medicine Revenue in 2025
Figure 21. North America Radiopharmaceutical for Nuclear Medicine Market Size YoY Growth (US$ Million), 2021–2032
Figure 22. North America Radiopharmaceutical for Nuclear Medicine Market Share by Country (2021–2032)
Figure 23. United States Radiopharmaceutical for Nuclear Medicine Market Size YoY Growth (US$ Million), 2021–2032
Figure 24. Canada Radiopharmaceutical for Nuclear Medicine Market Size YoY Growth (US$ Million), 2021–2032
Figure 25. Europe Radiopharmaceutical for Nuclear Medicine Market Size YoY Growth (US$ Million), 2021–2032
Figure 26. Europe Radiopharmaceutical for Nuclear Medicine Market Share by Country (2021–2032)
Figure 27. Germany Radiopharmaceutical for Nuclear Medicine Market Size YoY Growth (US$ Million), 2021–2032
Figure 28. France Radiopharmaceutical for Nuclear Medicine Market Size YoY Growth (US$ Million), 2021–2032
Figure 29. U.K. Radiopharmaceutical for Nuclear Medicine Market Size YoY Growth (US$ Million), 2021–2032
Figure 30. Italy Radiopharmaceutical for Nuclear Medicine Market Size YoY Growth (US$ Million), 2021–2032
Figure 31. Russia Radiopharmaceutical for Nuclear Medicine Market Size YoY Growth (US$ Million), 2021–2032
Figure 32. Ireland Radiopharmaceutical for Nuclear Medicine Market Size YoY Growth (US$ Million), 2021–2032
Figure 33. Asia-Pacific Radiopharmaceutical for Nuclear Medicine Market Size YoY Growth (US$ Million), 2021–2032
Figure 34. Asia-Pacific Radiopharmaceutical for Nuclear Medicine Market Share by Region (2021–2032)
Figure 35. China Radiopharmaceutical for Nuclear Medicine Market Size YoY Growth (US$ Million), 2021–2032
Figure 36. Japan Radiopharmaceutical for Nuclear Medicine Market Size YoY Growth (US$ Million), 2021–2032
Figure 37. South Korea Radiopharmaceutical for Nuclear Medicine Market Size YoY Growth (US$ Million), 2021–2032
Figure 38. Southeast Asia Radiopharmaceutical for Nuclear Medicine Market Size YoY Growth (US$ Million), 2021–2032
Figure 39. India Radiopharmaceutical for Nuclear Medicine Market Size YoY Growth (US$ Million), 2021–2032
Figure 40. Australia & New Zealand Radiopharmaceutical for Nuclear Medicine Market Size YoY Growth (US$ Million), 2021–2032
Figure 41. Latin America Radiopharmaceutical for Nuclear Medicine Market Size YoY Growth (US$ Million), 2021–2032
Figure 42. Latin America Radiopharmaceutical for Nuclear Medicine Market Share by Country (2021–2032)
Figure 43. Mexico Radiopharmaceutical for Nuclear Medicine Market Size YoY Growth (US$ Million), 2021–2032
Figure 44. Brazil Radiopharmaceutical for Nuclear Medicine Market Size YoY Growth (US$ Million), 2021–2032
Figure 45. Middle East & Africa Radiopharmaceutical for Nuclear Medicine Market Size YoY Growth (US$ Million), 2021–2032
Figure 46. Middle East & Africa Radiopharmaceutical for Nuclear Medicine Market Share by Country (2021–2032)
Figure 47. Israel Radiopharmaceutical for Nuclear Medicine Market Size YoY Growth (US$ Million), 2021–2032
Figure 48. Saudi Arabia Radiopharmaceutical for Nuclear Medicine Market Size YoY Growth (US$ Million), 2021–2032
Figure 49. UAE Radiopharmaceutical for Nuclear Medicine Market Size YoY Growth (US$ Million), 2021–2032
Figure 50. NRG Revenue Growth Rate in Radiopharmaceutical for Nuclear Medicine Business (2021–2026)
Figure 51. NTP Radioisotopes Revenue Growth Rate in Radiopharmaceutical for Nuclear Medicine Business (2021–2026)
Figure 52. JSC Isotope Revenue Growth Rate in Radiopharmaceutical for Nuclear Medicine Business (2021–2026)
Figure 53. ANSTO Revenue Growth Rate in Radiopharmaceutical for Nuclear Medicine Business (2021–2026)
Figure 54. China National Nuclear Corporation (CNNC) Revenue Growth Rate in Radiopharmaceutical for Nuclear Medicine Business (2021–2026)
Figure 55. IRE ELIT Revenue Growth Rate in Radiopharmaceutical for Nuclear Medicine Business (2021–2026)
Figure 56. Nordion Revenue Growth Rate in Radiopharmaceutical for Nuclear Medicine Business (2021–2026)
Figure 57. Polatom Revenue Growth Rate in Radiopharmaceutical for Nuclear Medicine Business (2021–2026)
Figure 58. Bottom-up and Top-down Approaches for This Report
Figure 59. Data Triangulation
Figure 60. Key Executives Interviewed

Our Clients